News Center

位置：

Honors Announcement

Group News

Media Reports

Innovation Leads Development in the New Era

Category:

Group News

发布时间：2018-03-02

【概要描述】 At the construction site of Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s drug R&D platform, pilot-scale testing facility, and industrialization support project—located at the northeast corner of the intersection of Xing’an Avenue and Lijiang Road in the High-tech Zone—Zhao Yongzheng, the company’s deputy general manager, braved the biting cold wind to hold final pre-construction coordination meetings with experts from the design institute regarding certain project adjustments. “By the end of the year, this national enterprise technology center, with a total investment of more than 430 million yuan and equipped with a world-class chemical-drug R&D team and state-of-the-art facilities, along with the National-Local Joint Laboratory for Key Technologies in Quality Control of Chemical Injection Products, will be fully operational here. In effect, Sihua Pharmaceutical will have entered a new era of comprehensive innovation-driven development.” The just-concluded year of 2017,

Innovation Leads Development in the New Era

At the construction site of Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s drug R&D platform, pilot-scale testing facility, and industrialization support project—located at the northeast corner of the intersection of Xing’an Avenue and Lijiang Road in the High-tech Zone—Zhao Yongzheng, the company’s deputy general manager, braved the biting cold wind to hold final pre-construction coordination meetings with experts from the design institute regarding certain project adjustments. “By the end of the year, this national enterprise technology center, with a total investment of more than 430 million yuan and equipped with a world-class chemical-drug R&D team and state-of-the-art facilities, along with the National-Local Joint Laboratory for Key Technologies in Quality Control of Chemical Injection Products, will be fully operational here. In effect, Sihua Pharmaceutical will have entered a new era of comprehensive innovation-driven development.”

In the just-concluded year of 2017, Siyao intensified supply-side structural reform, strengthening its high-end infusion segment while focusing on innovative drugs and first-in-class new drugs, increasing capital investment, accelerating efforts to address innovation gaps, and expediting the transformation of product functions.

Focusing on the cutting edge of chemical pharmaceutical formulations and active pharmaceutical ingredients, Siyao has directed its innovative vision toward national priority areas such as the research and development of major innovative drugs. To this end, it has established a series of innovation platforms, including academician workstations and a workstation led by Professor Jean-Marie Lehn, recipient of the Nobel Prize in Chemistry, thereby leveraging external expertise to align the company’s activities in innovative drug screening, development, and clinical research with international standards.

“Leveraging an internationally oriented innovation platform and aligning with the company’s product positioning, we invest nearly RMB 500 million annually in R&D. To date, these efforts have yielded initial results: we have filed applications for and are currently developing more than 160 new products, placing us among the top 10 domestic pharmaceutical companies in terms of the number of patent applications. This has fostered a positive, virtuous cycle of R&D and innovation,” a senior official told the author with great satisfaction. As a portfolio of competitive products has gradually obtained regulatory approval and been launched into the market, the company has delivered outstanding performance: in 2017, Sihua Pharmaceutical achieved year-on-year growth of over 30% in both sales revenue and profits and taxes. In January of this year, the company recorded a 120% year-on-year increase in sales revenue and a 150% year-on-year rise in profits and taxes, once again setting new historical records.

On the fifth day of the first lunar month, researchers at the Sihua Pharmaceutical Research Institute cut their holiday short and resumed work. “This year, we will establish close collaborative partnerships with numerous domestic clinical trial research centers to ensure the quality of our clinical studies. We plan to conduct more than 150 bioequivalence and clinical trials in areas such as the treatment of chronic obstructive pulmonary disease, hypertension, diabetes, liver fibrosis, bacterial and viral infectious diseases, neuropsychiatric disorders, fever, and pain. In addition, we will fully leverage the technological strengths of the Beijing–Tianjin region by collaborating on projects with more universities and research institutions, thereby enhancing our R&D capabilities and efficiency and striving to develop at least three first-in-class new drugs,” said Yin Dianshu, Chief Engineer of Sihua Pharmaceutical and Director of the Pharmaceutical Research Institute.

Looking to the future, the employees of Siyao are brimming with confidence: “While continuing to excel in the development of innovative drugs, we will also seize the opportunities presented by high-potential markets and aggressively pursue the development of blockbuster generic drugs. At the same time, we will rigorously conduct bioequivalence evaluations for our existing key products—embracing ‘two innovations’—to accelerate product approval processes and enhance the efficiency of R&D成果转化. Our goal is to elevate the company to the ranks of national demonstration enterprises for technological innovation, shift the sales mix from 60% generics to 30% new products, continuously expand our competitive production capacity, and strengthen our profitability. In doing so, we aim to truly transform ourselves from a ‘follower’ to a ‘leader’ in the field of pharmaceutical innovation, thereby making new contributions to our city’s biopharmaceutical industry!”

Keywords:

The Third Session of the Ninth Trade Union Congress and the Conference for Commending Outstanding Individuals Were Successfully Held

Shisi Pharmaceutical: Innovating in Large-Volume Parenteral Solutions to Catch Up with the World’s Cutting Edge

The Third Session of the Ninth Trade Union Congress and the Conference for Commending Outstanding Individuals Were Successfully Held

Shisi Pharmaceutical: Innovating in Large-Volume Parenteral Solutions to Catch Up with the World’s Cutting Edge